TITLE

De-oncogenic HPV E6/E7 vaccine gets enhanced antigenicity and promotes tumoricidal synergy with cisplatin

AUTHOR(S)
Chen, Shaochun; Liao, Chaowei; Lai, Yiukay; Fan, Yan; Lu, Gang; Wang, Hua; Zhang, Xiaoai; Lin, Marie C.M.; Leng, Shuilong; Kung, Hsiang-Fu
PUB. DATE
January 2014
SOURCE
Acta Biochimica et Biophysica Sinica;Jan2014, Vol. 46 Issue 1, p6
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In order to develop more effective therapeutic vaccines against cancers with high-risk human papillomavirus (HPV) infection, it is crucial to enhance the immunogenicity, eliminate the oncogenicity of oncoproteins, and take a combination of E7- and E6-containing vaccines. It has been shown recently that PE(ΔIII)-E7-KDEL3 (E7), a fusion protein containing the HPV16 oncoprotein E7 and the translocation domain of Pseudomonas aeruginosa exotoxin A, is effective against TC-1 tumor cells inoculated in mice, therefore, we engineered PE(ΔIII)-E6-CRL-KDEL3 (E6), the de-oncogenic versions of the E7 and E6 fusion proteins [i.e. PE(ΔIII)-E7(d)-KDEL3, E7(d), and PE(ΔIII)-E6(d)-CRL-KDEL3, E6(d)] and tested the immunoefficacies of these fusion proteins as mono- and bivalent vaccines. Results indicated that the E7(d) get higher immunogenicity than its wild type and the E6 fusion proteins augmented the immunogenicity and antitumor effects of their E7 counterparts. Furthermore, the bivalent vaccine system E7(d) plus E6(d), in the presence of cisplatin, showed the best tumoristatic and tumoricidal effects against established tumors in vivo. Therefore, it can be concluded that this novel therapeutic vaccine system, upon further optimization, may shed new light on clinical management of HPV-related carcinomas.
ACCESSION #
93398777

 

Related Articles

  • Cancer Immunotherapy Employing an Innovative Strategy to Enhance CD4+ T Cell Help in the Tumor Microenvironment. Song, Liwen; Yang, Ming-Chieh; Knoff, Jayne; Wu, T.-C.; Hung, Chien-Fu // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1 

    Chemotherapy and/or radiation therapy are widely used as cancer treatments, but the antitumor effects they produce can be enhanced when combined with immunotherapies. Chemotherapy kills tumor cells, but it also releases tumor antigen and allows the cross-presentation of the tumor antigen to...

  • Human Papillomavirus (HPV) Vaccine (Gardasil).  // AHFS Consumer Medication Information;Apr2018, p1 

    What is HPV? HPV vaccine - Why get vaccinated? Who should get HPV vaccine and when? Some people should not get HPV vaccine or should wait What are the risks from this vaccine? What if there is a moderate or severe reaction? The National Vaccine Injury Compensation Program How can I learn more?

  • Human Papillomavirus (HPV) Vaccine (Cervarix).  // AHFS Consumer Medication Information;Apr2018, p1 

    What is HPV? HPV vaccine - Why get vaccinated? Who should get this HPV vaccine and when? Some people should not get HPV vaccine or should wait What are the risks from this vaccine? What if there is a severe reaction? The National Vaccine Injury Compensation Program How can I learn more?

  • Cervical Cancer and Human Papilloma Virus Vaccine : Awareness and Acceptability among Nursing Staff in a Tertiary Health Care Hospital. Verma, Kalpana; Surwade Vidya M; Aggarwal, Rajani // Indian Journal of Public Health Research & Development;Jul-Sep2015, Vol. 6 Issue 3, p297 

    Background: Cervical Cancer is the second-most common cancer in women worldwide; which can be prevented by HPV vaccine. Objectives: (1) To assess the awareness about cancer cervix and associated risk factors. (2) To assess the awareness regarding HPV vaccine (3) To study the acceptability of the...

  • HPV TYPE DISTRIBUTION AND SEROPREVALENCE OF HPV-SPECIFIC ANTIBODIES IN VACCINATED WOMEN IN THE CZECH REPUBLIC. Tachezy, Ruth; Šnahelová, Jana; Ludvíková, Viera; Saláková, Martina; Hamšiková, Eva // Central European Journal of Public Health;2008 Supplement, Vol. 16, pS60 

    Objectives: Today two commercial prophylactic HPV vaccines have been licensed to prevent de novo HPV-16 and HPV-18 infection. Nowadays numbers of sexually active women are being vaccinated. It has been shown that vaccination of women with incident and/or persistent infection with the vaccine HPV...

  • The HPV Vaccine: Overcoming Barriers to Acceptance of a Medical Triumph. Emberger, Jennifer // AMA Journal of Ethics;Sep2015, Vol. 17 Issue 9, p854 

    The article discusses the need to overcome barriers for increased use of human papillomavirus (HPV) vaccine to prevent cancer, ethical and social surrounding HPV vaccination and efforts to promote the HPV vaccine and incorporate it into vaccination for both sexes.

  • HPV-Related Risk Perceptions and HPV Vaccine Uptake Among a Sample of Young Rural Women. Vanderpool, Robin; Casey, Baretta; Crosby, Richard // Journal of Community Health;Dec2011, Vol. 36 Issue 6, p903 

    Appalachia Kentucky is recognized for increased cervical cancer incidence, morbidity and mortality and lower rates of Pap testing. Understanding the predictors of Human Papillomavirus (HPV) vaccine uptake is warranted among this population. The purpose of this exploratory research is to...

  • Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. Lee, Sung; Kang, Tae; Knoff, Jayne; Huang, Zhuomin; Soong, Ruey-Shyang; Alvarez, Ronald; Hung, Chien-Fu; Wu, T.-C. // Cancer Immunology, Immunotherapy;Jul2013, Vol. 62 Issue 7, p1175 

    Despite the conventional treatments of radiation therapy and chemotherapy, the 5-year survival rates for patients with advanced-stage cervical cancers remain low. Cancer immunotherapy has emerged as an alternative, innovative therapy that may improve survival. Here, we utilize a preclinical...

  • Sequential Cisplatin Therapy and Vaccination with HPV16 E6E7L2 Fusion Protein in Saponin Adjuvant GPI-0100 for the Treatment of a Model HPV16+ Cancer. Peng, Shiwen; Wang, Joshua W.; Karanam, Balasubramanyam; Wang, Chenguang; Huh, Warner K.; Alvarez, Ronald D.; Pai, Sara I.; Hung, Chien-fu; Wu, T. -C.; Roden, Richard B. S. // PLoS ONE;Jan2015, Vol. 10 Issue 1, p1 

    Clinical studies suggest that responses to HPV16 E6E7L2 fusion protein (TA-CIN) vaccination alone are modest, and GPI-0100 is a well-tolerated, potent adjuvant. Here we sought to optimize both the immunogenicity of TA-CIN via formulation with GPI-0100 and treatment of HPV16+ cancer by...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics